Supplementary material: Prognostic and predictive value of microsatellite instability status among patients with colorectal cancer

This is a peer-reviewed supplementary table for the article 'Prognostic and predictive value of microsatellite instability status among patients with colorectal cancer' published in the Journal of Comparative Effectiveness Research.Supplementary Figure 1. Overall survival in (A) stage II CRC and (B) stage III patients according to MSI status.Supplementary Figure 2. Stage II CRC with high-risk features.Supplementary Figure 3. Overall survival in (A) MSI-H and (B) MSI-S stage II CRC patients with highest-risk features according to chemotherapy.Supplementary Figure 4. Stage II CRC without high-risk features.Supplementary Figure 5. Overall survival in (A) MSI-H stage III CRC patients with low-risk features and (B) MSI-H stage III CRC patients with high-risk features according to chemotherapy.Supplementary Figure A. Patient selection.Supplementary Figure B. Histogram for raw data and matched data (stage II MSI-H and high-risk features).Supplementary Figure C. Histogram for raw data and matched data (stage II MSI-H and without high-risk features).Supplementary Figure D. Histogram for raw data and matched data (stage II MSI-S and without high-risk features).Supplementary Table A. Baseline characteristics of MSI-H stage II CRC patients with high-risk features according to chemotherapy after propensity score matching.Supplementary Table B. Baseline characteristics of MSI-H stage II CRC patients without high-risk features according to chemotherapy after propensity score matching.Supplementary Table C. Baseline characteristics of MSI-L stage II CRC patients without high-risk features according to chemotherapy after propensity score matching.Supplementary Table D. Multivariate analysis for MSI known status stage II & III CRC patients.Summary: Objectives: Compare overall survival (OS) between microsatellite instability (MSI) high and MSI-stable and analyze the effect of chemotherapy on OS. Methods: National cancer database was queried for patients diagnosed with colorectal adenocarcinoma between 2010 and 2016. We evaluated the OS and the chemotherapy effect using Kaplan–Meier estimates and multivariate Cox regression analyses. Results: Total of 30,436 stage II patients and 30,302 stage III patients were included. In stage II with high-risk features and MSI-high, patients who received chemotherapy had better OS compared to patients who didn't receive chemotherapy. The same was found in stage II with no high-risk features and MSI-high group. Conclusion: Stage II colorectal cancer patients with high-risk features and MSI-high who received chemotherapy have better OS compared to patients who didn't receive chemotherapy.

此为发表于《比较疗效研究杂志》之文章《结直肠癌患者微卫星不稳定性状态之预后及预测价值》的同行评审补充表格。补充图表1：根据MSI状态，II期结直肠癌（A）和III期患者（B）的总生存期。补充图表2：具有高风险特征的II期结直肠癌。补充图表3：根据化疗，具有最高风险特征的MSI-H和MSI-S状态II期CRC患者（A）和（B）的总生存期。补充图表4：无高风险特征的II期CRC。补充图表5：根据化疗，MSI-H状态III期CRC患者（A）低风险特征和（B）高风险特征的总生存期。补充图表A：患者选择。补充图表B：原始数据和匹配数据（II期MSI-H和高风险特征）的直方图。补充图表C：原始数据和匹配数据（II期MSI-H且无高风险特征）的直方图。补充图表D：原始数据和匹配数据（II期MSI-S且无高风险特征）的直方图。补充表A：根据化疗和倾向评分匹配后，具有高风险特征的MSI-H状态II期CRC患者的基线特征。补充表B：根据化疗和倾向评分匹配后，无高风险特征的MSI-H状态II期CRC患者的基线特征。补充表C：根据化疗和倾向评分匹配后，MSI-L状态II期CRC患者无高风险特征的基线特征。补充表D：MSI已知状态II期&III期CRC患者的多变量分析。摘要：目标：比较MSI高和MSI稳定的总体生存期（OS），并分析化疗对OS的影响。方法：查询2010年至2016年间诊断为结直肠腺癌的全国癌症数据库。我们使用Kaplan–Meier估计和多元Cox回归分析评估OS和化疗效果。结果：包括总共30,436名II期患者和30,302名III期患者。在具有高风险特征和MSI高的II期中，接受化疗的患者与未接受化疗的患者相比，总生存期更好。同样的结果也出现在无高风险特征的MSI高的II期组中。结论：接受化疗的具有高风险特征和MSI高的II期结直肠癌患者与未接受化疗的患者相比，具有更好的总生存期。